Bronconex Acticap

Country: New Zealand

Lingwa: Ingliż

Sors: Medsafe (Medicines Safety Authority)

Ingredjent attiv:

Mometasone furoate 400ug (anhydrous)

Disponibbli minn:

Organon (New Zealand) Limited

INN (Isem Internazzjonali):

Mometasone furoate 400 µg (anhydrous)

Dożaġġ:

400 mcg/dose

Għamla farmaċewtika:

Powder for inhalation

Kompożizzjoni:

Active: Mometasone furoate 400ug (anhydrous) Excipient: Lactose

Unitajiet fil-pakkett:

Inhaler, metered, DPI, (sample), 14 dose units

Klassi:

Prescription

Tip ta 'preskrizzjoni:

Prescription

Manifatturat minn:

MSD International GmbH (Singapore Branch)

Indikazzjonijiet terapewtiċi:

Bronconex Acticap is indicated for prophylactic therapy in the management of patients with asthma of all severities, including patients who have been dependent upon either inhaled or systemically administered corticosteroids and non-corticosteroid-dependent patients inadequately controlled on other drug regimens.

Sommarju tal-prodott:

Package - Contents - Shelf Life: Inhaler, metered, DPI, (sample) - 14 dose units - 18 months from date of manufacture stored at or below 25°C - Inhaler, metered, DPI - 30 dose units - 18 months from date of manufacture stored at or below 25°C - Inhaler, metered, DPI - 60 dose units - 18 months from date of manufacture stored at or below 25°C

Data ta 'l-awtorizzazzjoni:

2000-12-05